BellamyL,CasasJP,HingoraniAD,WilliamsD., 2009.Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis,Lancet 373 1773 -9
RobertsonRP,HarmonJS, 2007.Pancreatic islet beta-cell and oxidative stress: the importance of glutathione peroxidase,Febs Lett 581 3743 -8
AljadaA,GhanimH,SaadehR, 2001.Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells,J Clin Endocrinol Metab 86 450 -3
ParkesDG,MaceKF,TrautmannME, 2013.Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone,GLP-1. Expert Opin Drug Discov 8 219 -44
AhrénB., 2011.GLP-1 for type 2 diabetes,Exp Cell Res 317 1239 -45
DharmalingamM,SriramU,BaruahMP, 2011.Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus,Indian J Endocrinol Metab 15 9 -17
BregenholtS,MøldrupA,BlumeN,KarlsenAE,Nissen FriedrichsenB,TornhaveD, 2005.The long-acting glucagonlike peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro,Biochem Biophys Res Commun 330 577 -84
RolinB,LarsenMO,GotfredsenCF,DeaconCF,CarrRD,WilkenM, 2002.The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice,Am J Physiol Endocrinol Metab 283 E745 -52
MeraniS,TruongW,EmamaulleeJA,TosoC,KnudsenLB,ShapiroAM, 2008.Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice,Endocrinology 149 4322 -8
1984.Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial,N Engl J Med 311 365 -72
CroomKF,MccormackPL, 2009.Liraglutide: a review of its use in type 2 diabetes mellitus,Drugs 69 1985 -2004
ShimodaM,KandaY,HamamotoS,TawaramotoK,HashiramotoM,MatsukiM, 2011.The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes,Diabetologia 54 1098 -108
AppelLJ,SacksFM,CareyVJ,ObarzanekE,SwainJF,MillerER, 2005.Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial,JAMA 294 2455 -64
HanefeldM,AppeltD,EngelmannK,SandnerD,BornsteinSR,GanzX, 2016.Serum and plasma levels of vascular endothelial growth factors in relation to quality of glucose control, biomarkers of inflammation, and diabetic nephropathy,Horm Metab Res 48 529 -34
TykhomyrovAA,ShramSI,GrinenkoTV, 2015.Role of angiostatins in diabetic complications,Biomed Khim 61 41 -56
LindblomR,HigginsG,CoughlanM, 2015.Targeting mitochondria and reactive oxygen species-driven pathogenesis in diabetic nephropathy,Rev Diabet Stud 12 134 -56
CaoHX,HeLQ,ShenYJ, 2004.Changes of SOD, GSH and MDA in renal tissues of diabetic hyperlipidemia rats,Zhong Xi Yi Jie He Xue Bao 2 36 -8
PadalkarRK,ShindeAV,PatilSM, 2012.Lipid profile, serum malondialdehyde, superoxide dismutase in chronic kidney diseases and type 2 diabetes mellitus,Biomed Res 23 207 -10
HaradaC,OkumuraA,NamekataK,NakamuraK,MitamuraY,OhguroH, 2006.Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy,Diabetes Res Clin Pract 74 249 -56
SunX,HanF,YiJ,HanL,WangB, 2011.Effect of aspirin on the expression of hepatocyte NF-B and serum TNF- in streptozotocin-induced type 2 diabetic rats,J Korean Med Sci 26 765 -70